Tassilo L A Wachsmann, Teuntje Poortvliet, Miranda H Meeuwsen, Dennis F G Remst, Marijke F Toes, Anne K Wouters, Renate S Hagedoorn, J H Frederik Falkenburg, Mirjam H M Heemskerk
{"title":"CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.","authors":"Tassilo L A Wachsmann, Teuntje Poortvliet, Miranda H Meeuwsen, Dennis F G Remst, Marijke F Toes, Anne K Wouters, Renate S Hagedoorn, J H Frederik Falkenburg, Mirjam H M Heemskerk","doi":"10.1016/j.ymthe.2025.02.035","DOIUrl":null,"url":null,"abstract":"<p><p>Antigen escape can compromise the efficacy of chimeric antigen receptor (CAR-) or T cell receptor (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR- with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens. Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR- and CAR-engineering to prevent antigen escape of multiple myeloma (MM). We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B*07:02, alongside a BCMA-targeting CAR. Those T cells, termed TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual-specificity. In the presence of both antigens however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition. Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogenous MM. In conclusion, we demonstrate general dual-specificity of TRaCR T cells but advise caution when using TRaCR T cells as strategy to target heterogenous tumors.</p>","PeriodicalId":19020,"journal":{"name":"Molecular Therapy","volume":" ","pages":""},"PeriodicalIF":12.1000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ymthe.2025.02.035","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Antigen escape can compromise the efficacy of chimeric antigen receptor (CAR-) or T cell receptor (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR- with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens. Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR- and CAR-engineering to prevent antigen escape of multiple myeloma (MM). We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B*07:02, alongside a BCMA-targeting CAR. Those T cells, termed TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual-specificity. In the presence of both antigens however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition. Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogenous MM. In conclusion, we demonstrate general dual-specificity of TRaCR T cells but advise caution when using TRaCR T cells as strategy to target heterogenous tumors.
期刊介绍:
Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.